Sedative Hypnotics, Benzodiazepines, Paralytics, and MFI Protocols

Sedative-Hypnotic Classification and Overview
  • Pharmacological Grouping:

    • Sedative-hypnotics are broadly categorized into three major pharmacological groups:

    • Barbiturates

    • Benzodiazepine-like drugs

    • Benzodiazepines

    • Benzodiazepines represent the first-line therapeutic choice for:

    • Acute management of anxiety

    • Most seizure disorders

    • Skeletal muscle spasms

    • Alcohol withdrawal syndrome

  • Pharmacological Effects and Systemic Considerations:

    • Lipid Solubility: Highly lipid-soluble, facilitating rapid penetration across the blood-brain barrier. Increasing the dose directly increases the pharmacological effect, progressing linearly from mild sedation to deep coma.

    • Cardiovascular System Effects:

    • Can produce significant hypotension and lead to cardiac arrest.

    • Airway and resuscitation equipment must be fully prepped prior to administration to manage severe hypotension, loss of protective airway reflexes, or respiratory arrest.

    • Basic airway maneuvers are initiated first; if high doses induce profound respiratory failure or obtundation, endotracheal intubation is required.

    • Respiratory System Effects:

    • Function as weak respiratory depressants in healthy individuals.

    • In patients with Chronic Obstructive Pulmonary Disease (COPD), benzodiazepines exacerbate hypoventilation.

    • In patients with partial upper airway obstructions, administration can precipitate complete upper airway obstruction.

    • Paradoxical Reactions:

    • Uncommonly, benzodiazepines induce paradoxical central nervous system excitation rather than sedation.

    • Manifestations include excessive motor activity, severe agitation, talkativeness, impulsivity, irritability, and extreme excitement.

  • Mechanism of Action (MOA):

    • Benzodiazepines potentiate the action of Gamma-Aminobutyric Acid (GABA), the primary inhibitory neurotransmitter in the central nervous system.

    • By binding to specific sites on the GABA-A receptor complex, they enhance GABA-mediated chloride influx, hyperpolarizing the postsynaptic membrane and inhibiting neuronal firing.

Benzodiazepine Pharmacology and Specific Agents
  • Midazolam (Versed):

    • Pharmacokinetics: Possesses short-term sedative-hypnotic effects; undergoes primary hepatic metabolism.

    • Indications:

    • Active seizure termination

    • Procedural sedation (e.g., synchronized cardioversion, transcutaneous pacing, fracture realignment, severe muscle spasms; administered alongside analgesia)

    • Severely anxious or combative patients (e.g., Excited Delirium Syndrome)

    • Sedation prior to intubation (administered in conjunction with fentanyl or ketamine)

    • Maintenance of ongoing sedation for intubated and mechanically ventilated patients

    • Contraindications:

    • Acute narrow-angle glaucoma

    • Acute alcohol intoxication

    • Uncorrected hypotension

    • Known hypersensitivity to benzodiazepines

    • Precautions: Requires a rigorous risk-versus-benefit evaluation prior to administration in unstable clinical conditions.

    • Adult Dosing Regimens:

    • Seizure Control (IV/IO): 0.1 mg/kg0.1\,\text{mg/kg} administered via slow IV push or IO. Single maximum dose is 5 mg5\,\text{mg}. Repeat every 10−15 minutes10-15\,\text{minutes} as needed to a total maximum dose of 20 mg20\,\text{mg}.

    • Seizure Control (IM): 0.2 mg/kg0.2\,\text{mg/kg} IM. Single maximum dose is 10 mg10\,\text{mg}.

    • Combative Behavior / Sympathomimetic Overdose: Requires a minimum systolic blood pressure above 100 mmHg100\,\text{mmHg}. IM route is preferred for severely combative patients without vascular access (0.1 mg/kg0.1\,\text{mg/kg} to 0.2 mg/kg0.2\,\text{mg/kg}; initial administration of 5 mg5\,\text{mg} is recommended if weight is uncertain). If an IV is in place, slow IV push facilitates faster onset.

    • Pediatric Dosing Regimens:

    • Definition of Pediatric Age: Onset of puberty down to neonates. Physical size and development must be factored into dose selection (e.g., a 13 year old13\,\text{year old} patient weighing 80 kg80\,\text{kg} without signs of puberty may require adult-tier dosing starting conservatively).

    • Pediatric Seizures / Sedation (IM): 0.1 mg/kg0.1\,\text{mg/kg} IM. Split the volume equally between two distinct anatomical IM sites (e.g., vastus lateralis muscles) if volume is large, to a total maximum dose of 10 mg10\,\text{mg}.

    • Pediatric Sedation (IV): 0.05 mg/kg0.05\,\text{mg/kg} slow IV push.

    • Pediatric Intranasal (IN): 0.1 mg/kg0.1\,\text{mg/kg} split equally between nostrils.

    • Blood Pressure Constraint: Strict blood pressure thresholds must be verified prior to pediatric administration.

  • Lorazepam (Ativan):

    • Storage and Stability: Intravenous supply vials require continuous refrigeration. If left at room temperature, parenteral vials remain stable for only 24 hours24\,\text{hours}. Sublingual (SL) tablets (0.5 mg0.5\,\text{mg} or 1 mg1\,\text{mg}) are stable at room temperature.

    • Administration Requirements: Parenteral IV lorazepam must be diluted with an equal volume of Normal Saline (0.9% NaCl0.9\%\,\text{NaCl}) prior to IV injection.

    • Geriatric Considerations: Elderly patients exhibit heightened susceptibility to extrapyramidal symptoms, profound sedation, and acute confusion. Doses must be reduced by 50%50\% relative to younger adults.

    • Indications and Adult Dosing:

    • Anxiety: 0.5−1 mg0.5-1\,\text{mg} sublingual every 15 minutes15\,\text{minutes} as needed.

    • Alcohol Withdrawal: 1 mg1\,\text{mg} sublingual every 20 minutes20\,\text{minutes} to a maximum cumulative dose of 4 mg4\,\text{mg} (indicated for conscious patients exhibiting severe tremors, nausea, vomiting, and profuse diaphoresis; concurrent cardiac etiology must be ruled out). Reduce dose by 50%50\% (0.5 mg0.5\,\text{mg}) in geriatric patients. If withdrawal progresses to active seizures, transition immediately to IV midazolam or parenteral benzodiazepines.

    • Acute Agitation / Sedation: 2 mg2\,\text{mg} slow IV push or IM every 30 minutes30\,\text{minutes}.

    • Pediatric Dosing:

    • Seizures: 0.1 mg/kg0.1\,\text{mg/kg} slow IV push, IN, IO, or IM.

    • Sedation: 0.05 mg/kg0.05\,\text{mg/kg} slow IV push, maximum single dose of 2 mg2\,\text{mg}.

    • Anxiety (Patients >20 kg> 20\,\text{kg}): 0.5−1 mg0.5-1\,\text{mg} sublingual every 15 minutes15\,\text{minutes} as needed. Contraindicated in pediatric patients weighing under 20 kg20\,\text{kg}.

  • Diazepam (Valium):

    • Pharmacodynamics: Benzodiazepine agonist acting on the inhibitory GABA receptor complex.

    • Administration Rules: Do NOT dilute or mix diazepam with any other intravenous medications or solutions. Inject directly into the IV tubing as close to the venous insertion site as possible. Absorption via the IM route is extremely erratic and painful; therefore, IM administration is strictly avoided.

    • Dose Equivalency: 5 mg5\,\text{mg} of intravenous diazepam is therapeutically equivalent to 2 mg2\,\text{mg} of intravenous lorazepam.

    • Indications and Adult Dosing:

    • Seizure Control: 5−10 mg5-10\,\text{mg} slow IV push every 10−15 minutes10-15\,\text{minutes} to a total cumulative maximum dose of 30 mg30\,\text{mg}.

    • Clinical Escalation Principle: If maximal doses of a benzodiazepine fail to control refractory seizures or alcohol withdrawal symptoms, repeated administration of the same agent yields diminishing returns; clinical management must immediately escalate to alternative or stronger therapeutic classes (e.g., ketamine or barbiturates).

  • Benzodiazepine Antidote: Flumazenil:

    • Mechanism of Action: Direct competitive antagonist that completely inhibits the actions of benzodiazepines at the GABA receptor complex.

    • Indications: Complete or partial reversal of the sedative and respiratory depressant effects of benzodiazepines in cases of known, pure benzodiazepine overdose.

    • Contraindications:

    • Known hypersensitivity to flumazenil or benzodiazepines.

    • Patients receiving benzodiazepines for life-threatening conditions (e.g., active status epilepticus or elevated intracranial pressure [ICP]).

    • Patients with a known seizure disorder or lower seizure threshold.

    • Unknown drug overdoses or mixed/poly-pharmacy overdoses (e.g., co-ingestion of benzodiazepines with opioids, tricyclic antidepressants, or sympathomimetics).

    • Clinical Risks and Administration Rules:

    • Reversing benzodiazepine binding in chronic users or mixed overdoses can instantly precipitate life-threatening, refractory seizures and acute withdrawal syndrome.

    • Monitor respiratory rate and oxygenation for a minimum of 2 hours2\,\text{hours} post-administration; long-acting benzodiazepines outlast the elimination half-life of flumazenil, leading to recurrent respiratory depression.

    • Administration Rate: Must be given as a slow IV push. Do not exceed an injection rate of 0.2 mg/min0.2\,\text{mg/min} in pediatric patients or 0.5 mg/min0.5\,\text{mg/min} in adult patients.

Neuromuscular Blocking Drugs (Paralytics)
  • General Principles:

    • Mechanism: Competitive or depolarizing blockade of nicotinic acetylcholine (ACh\text{ACh}) receptors on the skeletal muscle neuromuscular junction, preventing muscle depolarization and contraction.

    • Crucial Clinical Safety Mandate: Neuromuscular blockers cause complete muscle paralysis but possess ZERO sedative, hypnotic, or analgesic properties. Paralyzed patients without adequate anesthesia remain fully conscious, able to see, hear, and feel pain while entirely unable to move or communicate ("locked-in syndrome"). Neuromuscular blockers must NEVER be administered without prior induction of complete sedation and analgesia.

    • Classes: Depolarizing agents vs. Nondepolarizing agents.

  • Depolarizing Agent: Succinylcholine (Sux):

    • Mechanism: Binds to nicotinic receptors and induces persistent depolarization of the motor endplate, triggering transient, visible muscle twitching (fasciculations) followed immediately by flaccid paralysis. Onset occurs within 30−60 seconds30-60\,\text{seconds}, with a short duration of action (5−10 minutes5-10\,\text{minutes}).

    • Indications: Preferred agent for Medication-Facilitated Intubation (MFI) induction due to rapid onset and brief duration, allowing spontaneous respirations to resume rapidly if airway capture fails. It is NOT utilized for post-intubation sedation or maintenance paralysis.

    • Electrolyte/Tissue Warnings: Causes massive efflux of intracellular potassium into the extracellular space. Strictly contraindicated in patients with hyperkalemia or conditions predisposing to severe hyperkalemia (e.g., severe burn injuries >24 hours> 24\,\text{hours} old, major crushing trauma, extensive skeletal muscle denervation/myopathies).

    • Malignant Hyperthermia Warning: Absolute contraindication in patients with a personal or family history of Malignant Hyperthermia.

    • Storage: Must be stored under continuous refrigeration (2−8 ∘C2-8\,^\circ\text{C}). Unopened multi-dose vials kept at room temperature remain stable for a maximum of 14−28 days14-28\,\text{days} (must be explicitly dated upon removal from refrigeration).

    • Adverse Effects: Severe, vagally-mediated bradycardia (especially in pediatric patients <8 years old< 8\,\text{years old} or with repeated dosing); treatable with atropine.

    • Dosing (Actual Body Weight):

    • Adult MFI Induction: 1−1.5 mg/kg1-1.5\,\text{mg/kg} IV single dose (e.g., a 90 kg90\,\text{kg} adult receives 90−135 mg90-135\,\text{mg} IV push).

    • Small Pediatric Patients: 1.5−2 mg/kg1.5-2\,\text{mg/kg} IV push (maximum single dose 150 mg150\,\text{mg}; higher weight-based volume required due to expanded distribution volume).

    • Adolescents / Older Children: 1−1.5 mg/kg1-1.5\,\text{mg/kg} IV push (maximum single dose 150 mg150\,\text{mg}).

  • Malignant Hyperthermia (MH):

    • Pathophysiology: Genetically determined pharmacogenetic disorder characterized by hypermetabolism involving uncontrolled, massive release of calcium from the sarcoplasmic reticulum in skeletal muscle cells.

    • Triggers: Succinylcholine and volatile inhalation anesthetics (e.g., halothane, isoflurane).

    • Clinical Signs: Rapid elevation of core body temperature (rising up to 40−43 ∘C40-43\,^\circ\text{C}), severe generalized muscle rigidity/spasms, profuse diaphoresis, hyperkalemic cardiac dysrhythmias, unstable blood pressure, severe metabolic acidosis.

    • Risk Factors: Higher susceptibility in children under 8 years old8\,\text{years old} with undiagnosed myopathies (e.g., Duchenne muscular dystrophy). A previous uncomplicated exposure to anesthesia does NOT rule out future risk of MH.

    • Specific Antidote: Dantrolene, which acts directly on skeletal muscle ryanodine receptors to inhibit calcium release, terminating muscle contraction and hypermetabolism.

  • Nondepolarizing Agents:

    • Mechanism: Competitive antagonists that block acetylcholine from binding to postsynaptic nicotinic receptors without causing depolarization. Fasciculations do NOT occur.

    • Order of Muscle Paralysis Progression: Eyelids →\rightarrow muscles of mastication →\rightarrow digits →\rightarrow jaw manipulation →\rightarrow limbs →\rightarrow abdomen →\rightarrow glottis →\rightarrow intercostals and diaphragm.

    • Rocuronium (Rock):

    • Pharmacokinetics: Onset 1−2 minutes1-2\,\text{minutes}; intermediate duration of 20−40 minutes20-40\,\text{minutes}.

    • Indications: Induction for MFI when succinylcholine is contraindicated, or maintenance of paralysis post-intubation.

    • Critical Safety Caveat: Rocuronium outlasts most short-acting sedatives. Continuous monitoring for signs of waning sedation is required (e.g., lacrimation/tearing, coughing, gagging, fighting/biting the endotracheal tube, sudden tachycardia, hypertension). Sedation must be re-administered before paralytic re-dosing.

    • Contraindications: Known hypersensitivity to bromides; suspected difficult airway in a self-ventilating patient where rescue bag-valve-mask ventilation or rescue cricothyroidotomy would be impossible once paralyzed.

    • Cardiovascular Effects: Minor increases in heart rate and blood pressure; may induce rare bronchospasm; causes NO systemic histamine release.

    • Storage: Refrigerated storage preferred; stable at room temperature outside refrigeration for up to 60 days60\,\text{days} if strictly dated.

    • Dosing (Ideal Body Weight [IBW]):

      • Adult Loading / Induction Dose: 0.6−1.2 mg/kg0.6-1.2\,\text{mg/kg} IV push (e.g., a 5′5"5'5" female with IBW of 57 kg57\,\text{kg} receives 34−68 mg34-68\,\text{mg} IV push).

      • Adult Maintenance / Repeat Dose: 0.6 mg/kg0.6\,\text{mg/kg} IV push.

    • Vecuronium:

    • Pharmacokinetics: Nondepolarizing neuromuscular blocker.

    • Dosing (Ideal Body Weight [IBW]):

      • Adult Loading Dose: 0.08−0.15 mg/kg0.08-0.15\,\text{mg/kg} slow IV push.

      • Pediatric Loading Dose: 0.1−0.15 mg/kg0.1-0.15\,\text{mg/kg} slow IV push.

    • Pancuronium:

    • Dosing (Ideal Body Weight [IBW]):

      • Adult and Pediatric Loading Dose: 0.06−0.1 mg/kg0.06-0.1\,\text{mg/kg} IV push.

      • Maintenance Dose: 0.01 mg/kg0.01\,\text{mg/kg} IV push.

      • Pediatric Adjustment: If succinylcholine was initially administered as the induction agent, decrease the initial pancuronium dose by 13\frac{1}{3}. Administer incremental doses of 0.01 mg/kg0.01\,\text{mg/kg} until target relaxation is achieved.

The 7 Ps of Medication-Facilitated Intubation (MFI)
  • 1. Preparation and Positioning:

    • Patient Preparation: Inform patient/family and obtain consent (express or implied). Assign specific, unambiguous roles to resuscitation team members (minimum two personnel dedicated to airway management).

    • Positioning: Align the anatomical axes (ear-to-sternal-notch / sniffing position). Elevate/ramp obese patients. Transfer patients found on the floor onto a stretcher to optimize height and mechanical access prior to intubation attempts.

    • LEMON Airway Assessment Tool:

    • L (Look externally): Evaluate facial structure, trauma, beard, retrognathia.

    • E (Evaluate 3-3-2 rule): 3 fingerbreadths mouth opening, 3 fingerbreadths hyoid-to-chin distance, 2 fingerbreadths thyroid notch-to-hyoid distance.

    • M (Mallampati / LEON score): Assess visibility of soft palate, uvula, and fauces.

    • O (Obstruction / Obesity): Assess for upper airway edema, burns, mass, epiglotitis, or severe obesity.

    • N (Neck mobility): Assess neck extension capability; note rigid cervical collar limitations.

    • Equipment Checklist:

    • Endotracheal (ET) tubes: Desired size, plus one size larger (+0.5 mm+0.5\,\text{mm}) and one size smaller (−0.5 mm-0.5\,\text{mm}) (e.g., for an 8.0 mm8.0\,\text{mm} target, prepare 7.5 mm7.5\,\text{mm} and 8.5 mm8.5\,\text{mm} tubes).

    • 10 mL10\,\text{mL} syringe (test pilot cuff inflation).

    • Backup supraglottic airways (i-Gel, King LT, LMA).

    • Surgical cricothyroidotomy kit.

    • Laryngoscope handle and tested blades (direct or video laryngoscope).

    • Endotracheal tube stylet or intubating bougie (routine bougie use strongly recommended for high first-pass success).

    • Sterile water-soluble lubricant.

    • Continuous Waveform End-Tidal CO2\text{CO}_2 (ETCO2\text{ETCO}_2) capnography adapter attached directly to the Bag-Valve-Mask (BVM).

    • Stethoscope, tube securement device, and bedside suction (suction powered ON, unkinked, and positioned at the head of the bed).

    • Medication Preparation: Draw up induction sedatives, induction paralytics, post-intubation maintenance sedatives, post-intubation paralytics, and pretreatment agents.

  • 2. Preoxygenation:

    • Goal: Achieve complete alveolar nitrogen washout, establishing a functional intra-pulmonary oxygen reservoir to prevent arterial desaturation during apnea.

    • Technique: High-flow nasal cannula at 15−25 L/min15-25\,\text{L/min} combined with a BVM or Non-Rebreather Mask (NRB) flush at 15−25 L/min15-25\,\text{L/min} for a minimum of 3−5 minutes3-5\,\text{minutes}.

  • 3. Pretreatment:

    • Administer adjuncts 3 minutes3\,\text{minutes} prior to induction to mitigate physiological surges caused by laryngoscopy:

    • Push-Dose Vasopressors: Bolus pressors to prevent catastrophic post-induction hypotension secondary to loss of sympathetic tone and positive pressure ventilation.

    • Atropine: Indicated in pediatric patients to prevent reflex bradycardia.

    • Ondansetron (Zofran): Indicated in active emesis or severe head injury to prevent aspiration and spikes in intracranial pressure (ICP).

  • 4. Paralysis with Sedation (Induction):

    • Administer selected induction agent (Fentanyl, Midazolam, Ketamine, or Propofol).

    • Wait 2−3 minutes2-3\,\text{minutes} for full therapeutic onset.

    • Assess jaw tone and respiratory effort: if jaw stiffness prevents laryngoscopy or resistance remains, administer the neuromuscular blocker (Succinylcholine or Rocuronium).

  • 5. Protection and Positioning:

    • Maintain inline cervical stabilization if trauma is suspected; perform manual airway positioning maneuvers.

  • 6. Placement with Proof:

    • Pass the endotracheal tube under direct or video visualization through the vocal cords until the proximal cuff passes the cords by 2−3 cm2-3\,\text{cm} (typical depth mark at teeth is 21−23 cm21-23\,\text{cm} in adults).

    • Primary Confirmation: Auscultate epigastrium first (must be silent). Auscultate bilateral lung apices and lateral bases for equal breath sounds. If breath sounds are present on the right but absent on the left, right mainstem bronchus intubation has occurred; deflate cuff, withdraw tube 1−2 cm1-2\,\text{cm}, re-inflate cuff, and re-auscultate.

    • Secondary Confirmation: Mandatory continuous quantitative waveform ETCO2\text{ETCO}_2 detection showing square-wave capnography.

    • Secure tube with commercial holder; document depth mark at teeth.

  • 7. Post-intubation Management:

    • Continuous vital signs and capnography monitoring.

    • Re-administer sedatives/analgesics continuously or via intermittent bolus (e.g., post-intubation infusions: Fentanyl at 75 μg/h75\,\mu\text{g/h}, Midazolam at 2 mg/h2\,\text{mg/h}, or Ketamine at 45 mg/h45\,\text{mg/h}).

    • Administer long-acting paralytic (Rocuronium) if patient demonstrates ventilator dyssynchrony, fighting, or breath-stacking despite documented adequate depth of sedation.

Additional Analgesics, Pharmacological Scenarios, and Drug Toxicity
  • Non-Opioid and Inhaled Analgesics:

    • Penthrox (Methoxyflurane): Rapid-onset, self-administered inhaled non-opioid analgesic (3 mL3\,\text{mL} bottle). Provides effective rapid analgesia during IV placement or acute musculoskeletal trauma. Instruct patient on covering the dilutor hole for higher concentration.

    • Ketorolac (Toradol): Non-steroidal anti-inflammatory drug (NSAID) (10−30 mg10-30\,\text{mg} IV/IM). Primary first-line agent for acute renal colic (kidney stones) by inhibiting prostaglandin synthesis, relieving ureteral smooth muscle spasm and capsular swelling. Also effective for acute localized back strain. Absolutely contraindicated in active hemorrhage/bleeding (e.g., open fractures, trauma) due to platelet inhibition, severe renal impairment, or NSAID/asthma triad.

    • Ketamine (Sub-dissociative Analgesia): Dose of 0.2−0.5 mg/kg0.2-0.5\,\text{mg/kg} slow IV push over 2 minutes2\,\text{minutes} diluted in normal saline (13−33 mg13-33\,\text{mg} for a average adult). Effective for refractory back spasms or severe acute pain. Emergence delirium (12%12\% incidence) is managed by maintaining a low-stimulation environment or administering low-dose Midazolam (1−2.5 mg1-2.5\,\text{mg} IV).

  • Propofol (Diprivan):

    • Pharmacology: Short-acting intravenous hypnotic/sedative presented as an oil-in-water lipid emulsion ("milk of amnesia").

    • Induction Dosing: 1−2.5 mg/kg1-2.5\,\text{mg/kg} IV push (e.g., a 77 kg77\,\text{kg} adult requires ≈77−190 mg\approx 77-190\,\text{mg} IV push).

  • Critical Drug Interactions and Adverse Effects:

    • Monoamine Oxidase Inhibitors (MAOIs): Administration of opioids (Fentanyl or Morphine) within 14 days14\,\text{days} of MAOI therapy can trigger fatal Serotonin Syndrome, extreme hyperthermia, and hypertensive crisis.

    • Fentanyl Rapid Injection: Rapid high-dose IV push administration of fentanyl causes Rigid Chest Syndrome (wooden chest syndrome), preventing chest wall expansion; managed immediately with neuromuscular blockade and naloxone.

    • Etomidate Usage Trends: Historically popular for rapid induction, etomidate has been phased out or reduced in prehospital ground protocols primarily due to high procurement cost and limited availability compared to ketamine and midazolam.